Please assess the completion status of the following clinical trial:

Trial Title: Cetuximab and Capecitabine in Treating Patients With Metastatic Colorectal Cancer That Failed Irinotecan Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of metastatic colorectal cancer~* Measurable disease~* Disease progression during prior fluoropyrimidine-containing therapy comprising irinotecan with or without oxaliplatin~  * Received standard first- and second-line irinotecan and oxaliplatin-based therapy~    * Patients who completed 1 prior treatment for metastatic disease but refused standard second-line therapy are eligible~ * Patients who's disease progressed within 6 months of previous therapy are eligible~* EGFR negative patients allowed~* No untreated or uncontrolled brain metastasis~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Absolute neutrophil count ≥ 1,500/μL~* Platelet count ≥ 100,000/μL~* ALT ≤ 5 times upper limit of normal (ULN)~* Alkaline phosphatase ≤ 5 times ULN~* Serum creatinine ≤ 1.5 mg/dL~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No other prior malignancy within the past 5 years except nonmelanoma skin cancer or carcinoma in situ of the cervix~* No serious intercurrent infections or medical problems~* No active or uncontrolled infections~* No significant history of uncontrolled cardiac disease, including any of the following:~  * Uncontrolled hypertension~ * Unstable angina~ * Myocardial infarction within the past 6 months~ * Uncontrolled congestive heart failure~ * Cardiomyopathy with decreased ejection fraction~* No prior severe infusion reaction to a monoclonal antibody~* No known dihydropyrimidine dehydrogenase deficiency or evidence of past hypersensitivity to fluoropyrimidine~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No more than 2 prior treatments for metastatic colorectal cancer~* More than 2 weeks since prior therapy~* Prior radiotherapy allowed if \< 30% of bone marrow involvement~* No other concurrent investigational agents~* No concurrent highly active antiretroviral therapy for HIV-positive patients~* No prior therapy that specifically and directly targets the EGFR pathway

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Cetuximab 400mg/m2 IV on day 1 over 2 hours then 250 mg/m2 over 1 hour weekly + Xeloda(Capecitabine) 1000mg/m2 BID on days 1-14 repeated every 21 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).